Buscar
Mostrando ítems 1-10 de 23
Actividad antitumoral del nuevo análogo de desmopresina [V⁴Q⁵] dDAVP sobre células de carcinoma mamario
(Universidad Nacional de Quilmes, 2015-03-20)
La desmopresina (1-deamino-8-D-arginina vasopresina o dDAVP) es un análogo sintético de la hormona vasopresina con propiedades hemostáticas y antitumorales. Nuestro laboratorio ha conducido el diseño racional de nuevos ...
Desmopressin in canine mammary carcinoma: Comments on the importance of the administration route
(Wiley Blackwell Publishing, Inc, 2021-09)
Several years ago, we proposed the haemostatic peptide desmopressin (1-desamino-8-d-arginine vasopressin; dDAVP) as a potential anti-metastatic agent to be used during surgical excision of locally advanced tumours. A ...
The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models
(Spandidos Publ Ltd, 2015-06)
Desmopressin (dDAVP) is a safe haemostatic agent with previously reported antitumour activity. It acts as a selective agonist for the V2 vasopressin membrane receptor (V2r) present on tumour cells and microvasculature. The ...
Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells
(Frontiers Research Foundation, 2017-01)
Neuroendocrine tumors (NETs) comprise a heterogeneous group of malignancies that express neuropeptides as synaptophysin, chromogranin A (CgA), and specific neuronal enolase (NSE), among others. Vasopressin (AVP) is a ...
Addition of vasopressin synthetic analogue [V4Q5]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models
(Springer, 2016-08)
[V4Q5]dDAVP is a novel 2nd generation vasopressin analogue with robust antitumour activity against metastatic breast cancer. We recently reported that, by acting on vasopressin V2r membrane receptor present in tumour cells ...
Anticancer activity of repurposed hemostatic agent desmopressin on AVPR2‑expressing human osteosarcoma
(Spandidos Publications, 2021-03-26)
Osteosarcoma is the most prevalent primary bone malignancy. Due to its high aggressiveness, novel treatment strategies are urgently required to improve survival of patients with osteosarcoma, especially those with advanced ...
Development and therapeutic potential of vasopressin synthetic analog [V4Q5]dDAVP as a novel anticancer agent
(Elsevier Academic Press Inc., 2020-01)
Since its discovery, arginine vasopressin (AVP) was subjected to several modifications with the aim of obtaining novel derivatives with increased potency and selectivity for biomedical use. Desmopressin (dDAVP) is a first ...
In vitro and in vivo evaluation of desmopressin-loaded poly(D,L-lactic-co-glycolic acid) nanoparticles for its potential use in cancer treatment
(Future Medicine, 2018-11)
Aim: To develop and characterize the antitumor activity of poly(D,L-lactic-co-glycolic acid) nanoparticles loaded with hemostatic and anticancer drug desmopressin (dDAVP). Materials & methods: After full physicochemical ...
Preclinical efficacy of [V 4 Q 5 ]dDAVP, a second generation vasopressin analog, on metastatic spread and tumor-associated angiogenesis in colorectal cancer
(Korean Cancer Association, 2018-06)
Purpose Control of metastatic spread of colorectal cancer (CRC) remains as a major therapeutic challenge. [V 4 Q 5 ]dDAVP is a vasopressin peptide analog with previously reported anticancer activity against carcinoma tumors. ...